Prevalence and predictors of coronary artery stent re-stenosis in patients with cancer with prior history of percutaneous coronary intervention: A nationwide analysis.

Abstract

e24018 Background: Data regarding the prevalence, and predictors of development of in-stent restenosis (ISR) in cancer patients undergoing percutaneous coronary intervention (PCI) are scarce. This study aimed to identify factors associated with the development of ISR following PCI in cancer patients. Methods: This is a retrospective cohort study using the National Inpatient Sample(NIS) from 2016 to 2020. Discharges with ICD-10 CM code indicating stenosis of coronary artery stent, and secondary ICD-10 CM code indicating cancer, and prior history of PCI were included. Primary outcome was development of ISR. Multivariate logistic regression model was used to identify predictors of ISR development, and p value of less than 0.05 was considered significant. Results: There were 873,320 patients who met inclusion criteria, among which 4060 patients were admitted for coronary stent re-stenosis. Mean age of included patients was 73, and 31% were females. The prevalence rate of in-stent restenosis was 0.46%. Factors associated with increased odds of development of ISR included diabetes (OR 1.31, 95% CI 1.13-1.51, p < 0.001), dyslipidemia (OR 1.92, 95% CI 1.60-2.31, p < 0.001), congestive heart failure (OR 1.78, 95% CI 1.52-2.06, p < 0.01), carotid disease (OR 1.99, 95% CI 1.43-2.78, p < 0.001), and aortic disease (OR 1.83, 95% CI 1.12-2.98, p 0.01). Age, gender, race, median household income, hospital location and hospital teaching status didn’t exhibit statistically significant increased risk. Conclusions: The prevalence of in-stent restenosis was 0.46%. Appropriate management of risk factors such as diabetes, dyslipidaemia, congestive heart failure is prudent to prevent development of ISR in cancer patients, underscoring the importance of regular cardiology follow up, along with routine cancer care.